OHE Lunchtime Seminar with Dr. Aslam Anis, The University of British Columbia. The seminar will discuss the impact of the pan-Canadian Pharmaceutical Alliance “tiered pricing” framework (a flexible 'price-cap' regulation) on generic entry, the resulting drug expenditure levels from a drug plans’ perspective and the implications of price-capping policies on drug shortages.
A new publication in the European Journal of Health Economics identifies potential challenges of ATMPs in view of current health technology assessment (HTA) methodology and explores potential solutions to these challenges. Three key topics are explored: uncertainty, discounting, and health outcomes and value. A series of recommendations are proposed.
Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Action (MoCA) initiative, and discuss why it can be beneficial to all parties involved and how it can improve decision making for – and access to – orphan drugs in European countries.
Just published are two new reports that explore the use of real world evidence for coverage and formulary decisions. The publications represent 1) the background paper to the 2017 ICER Membership Policy Summit and 2) a follow up paper based on the discussion at the Summit.